[{"address1": "The Mediaworks", "address2": "191 Wood Lane White City", "city": "London", "zip": "W12 7FP", "country": "United Kingdom", "phone": "44 20 3829 6230", "website": "https://www.autolus.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 463, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christian Martin Itin Ph.D.", "age": 60, "title": "CEO & Director", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 2494371, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Martin  Pule M.D., MBBS", "age": 52, "title": "Founder, Senior VP & Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert F. Dolski", "age": 53, "title": "Senior VP & CFO", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Vann", "age": 59, "title": "Senior VP & COO", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Brochu", "age": 68, "title": "Senior VP & Chief Technical Officer", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Swan", "age": 59, "title": "Senior VP & Chief Human Resources Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brent  Rice", "age": 58, "title": "Senior VP, Chief Commercial Officer & Site Head of US", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Olivia  Manser", "title": "Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alex  Driggs", "title": "Senior VP of Legal Affairs & General Counsel and Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Chris  Williams", "age": 44, "title": "Chief Business Officer", "yearBorn": 1980, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.79, "open": 1.85, "dayLow": 1.78, "dayHigh": 1.92, "regularMarketPreviousClose": 1.79, "regularMarketOpen": 1.85, "regularMarketDayLow": 1.78, "regularMarketDayHigh": 1.92, "payoutRatio": 0.0, "beta": 2.064, "forwardPE": -2.630137, "volume": 991779, "regularMarketVolume": 991779, "averageVolume": 1245187, "averageVolume10days": 1106230, "averageDailyVolume10Day": 1106230, "bid": 1.83, "ask": 1.98, "bidSize": 1, "askSize": 1, "marketCap": 510954240, "fiftyTwoWeekLow": 1.68, "fiftyTwoWeekHigh": 6.625, "priceToSalesTrailing12Months": 50.634647, "fiftyDayAverage": 2.0806, "twoHundredDayAverage": 3.31335, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 120462824, "profitMargins": 0.0, "floatShares": 137438546, "sharesOutstanding": 266122000, "sharesShort": 9104667, "sharesShortPriorMonth": 9108530, "sharesShortPreviousMonthDate": 1738281600, "dateShortInterest": 1740700800, "sharesPercentSharesOut": 0.0342, "heldPercentInsiders": 0.18088, "heldPercentInstitutions": 0.86122, "shortRatio": 7.39, "shortPercentOfFloat": 0.0462, "impliedSharesOutstanding": 269838016, "bookValue": 1.792, "priceToBook": 1.0714285, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -270227008, "trailingEps": -1.22, "forwardEps": -0.73, "enterpriseToRevenue": 11.938, "enterpriseToEbitda": -0.572, "52WeekChange": -0.7267176, "SandP52WeekChange": 0.07465422, "quoteType": "EQUITY", "currentPrice": 1.92, "targetHighPrice": 14.0, "targetLowPrice": 7.6, "targetMeanPrice": 10.62222, "targetMedianPrice": 10.0, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 657067008, "totalCashPerShare": 2.469, "ebitda": -210782000, "totalDebt": 301172000, "quickRatio": 13.347, "currentRatio": 13.685, "totalRevenue": 10091000, "debtToEquity": 63.143, "revenuePerShare": 0.043, "returnOnAssets": -0.2211, "returnOnEquity": -0.82199997, "grossProfits": -118124000, "freeCashflow": -165016128, "operatingCashflow": -193170000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -21.62283, "financialCurrency": "USD", "symbol": "AUTL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Autolus Therapeutics plc", "longName": "Autolus Therapeutics plc", "corporateActions": [], "regularMarketTime": 1742413550, "exchange": "NMS", "messageBoardId": "finmb_562879769", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "regularMarketChange": 0.13, "regularMarketDayRange": "1.78 - 1.92", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1245187, "fiftyTwoWeekLowChange": 0.24000001, "fiftyTwoWeekLowChangePercent": 0.14285715, "fiftyTwoWeekRange": "1.68 - 6.625", "fiftyTwoWeekHighChange": -4.705, "fiftyTwoWeekHighChangePercent": -0.7101887, "fiftyTwoWeekChangePercent": -72.67176, "marketState": "REGULAR", "firstTradeDateMilliseconds": 1529674200000, "earningsTimestamp": 1742473800, "earningsTimestampStart": 1742473800, "earningsTimestampEnd": 1742473800, "earningsCallTimestampStart": 1742473800, "earningsCallTimestampEnd": 1742473800, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.22, "epsForward": -0.73, "epsCurrentYear": -0.91284, "priceEpsCurrentYear": -2.1033258, "fiftyDayAverageChange": -0.16060007, "fiftyDayAverageChangePercent": -0.077189304, "twoHundredDayAverageChange": -1.39335, "twoHundredDayAverageChangePercent": -0.42052606, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "regularMarketChangePercent": 7.282913, "regularMarketPrice": 1.92, "displayName": "Autolus Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-03-19"}]